Eli Lilly has announced a $1B investment to build a new biotech facility in Raheen (Ireland) for the manufacture of on-market monoclonal antibodies (mAbs). The site is expected to start production of Lilly’s new clinical products in 2026. The company said that this investment will expand Lilly’s manufacturing network for biologic active ingredients and support demand for existing products.
This news comes shortly after Samsung Biologics recently announced construction of its US$1.5B fifth plant in South Korea.